-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 J0VkB+VrWgsF0j3N2+FSju+ZVHkBr9c3ClYHdecGFQ1ORD2qUJfDu9vr++7kyckX
 q9EDcLmgRLNDQrwEClXUVw==

<SEC-DOCUMENT>0001157523-11-001357.txt : 20110303
<SEC-HEADER>0001157523-11-001357.hdr.sgml : 20110303
<ACCEPTANCE-DATETIME>20110303080020
ACCESSION NUMBER:		0001157523-11-001357
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110303
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110303
DATE AS OF CHANGE:		20110303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		11658436

	BUSINESS ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		7814330771

	MAIL ADDRESS:	
		STREET 1:		119 FOURTH AVE
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494-2725

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a6633053.htm
<DESCRIPTION>CELLDEX THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p>

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%">
      <tr>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">UNITED STATES</font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman">WASHINGTON,
      D.C. 20549</font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman"><b>FORM
      8-K</b></font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><br>CURRENT
      REPORT<br><font style="font-size: 10pt"><br style="font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman">PURSUANT
      TO SECTION 13 OR 15(d) OF</font><br><font style="font-size: 10pt; font-family: Times New Roman">THE
      SECURITIES EXCHANGE ACT OF 1934</font><font style="font-size: 10pt"><br style="font-size: 10pt"></font><br><br><font style="font-size: 10pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): &#160;</font><font style="font-size: 10pt; font-family: Times New Roman"><b>March
      3, 2011</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>CELLDEX
      THERAPEUTICS, INC.</b></font><br><font style="font-size: 10pt; font-family: Times New Roman">(Exact
      name of registrant as specified in its charter)</font><br>
    </p>
    <p style="text-align: center">
      <br>

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%">
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Delaware</b>
          </p>
        </td>
        <td style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px; width: 34%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>0-15006</b>
          </p>
        </td>
        <td style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>13-3191702</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (State or other jurisdiction
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            of incorporation)
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 34%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (Commission File Number)
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 33%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (IRS Employer
          </p>
          <p style="margin-bottom: 0px; margin-top: 0px">
            Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%">
      <tr>
        <td style="width: 25%">
          &#160;
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 50%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>119 Fourth Avenue<br>Needham, Massachusetts 02494-2725</b>
          </p>
        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 25%" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td colspan="3" style="text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices) (Zip Code)</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>(781)
      433-0771</b></font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-size: 10pt; font-family: Times New Roman">(Registrant&#8217;s
      telephone number, including area code)</font><font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt"></font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
      CFR 240.14a-12)</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))</font><br><font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))</font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; width: 100%">
      <tr>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="white-space: nowrap">
      Item 2.02.&#160;&#160;Results of Operations and Financial Condition.
    </p>
    <p>
      On March 3, 2011, Celldex Therapeutics, Inc. issued a press release
      announcing its financial results for the fourth quarter and fiscal
      2010.&#160;&#160;The full text of the press release is furnished as Exhibit 99.1
      hereto and is incorporated by reference herein.
    </p>
    <p>
      The information in this Item 2.02 of this Current Report on Form 8-K and
      Exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of
      Section 18 of the Securities Exchange Act of 1934, as amended (the
      &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that
      Section, nor shall such information be deemed incorporated by reference
      in any filing under the Securities Act of 1933, as amended (the
      &#8220;Securities Act&#8221;), or the Exchange Act, except as shall be expressly set
      forth by specific reference in such a filing.
    </p>
    <p style="white-space: nowrap">
      Item 9.01.&#160;&#160;Financial Statements and Exhibits.
    </p>
    <p>
      <u>(d) Exhibits</u>
    </p>
    <p>
      99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release of Celldex Therapeutics, Inc., dated March
      3, 2011.
    </p>
    <p>
      <br>
      <br>
      <br>
      <br>

    </p>
    <p style="text-align: center">
      [Remainder of page left blank intentionally]
    </p>
    <p>
      <br>
      <br>
      <br>
      <br>

    </p>
    <p>

    </p>
    <p>

    </p>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">SIGNATURE</font><br>
    </p>
    <p>
      Pursuant to the requirements of the Securities Exchange Act of 1934, as
      amended, the registrant has duly caused this report to be filed on its
      behalf by the undersigned hereunto duly authorized.
    </p>
    <p style="text-align: center">

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; margin-left:auto;margin-right:auto; width: 100%">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">
          &#160;
        </td>
        <td colspan="3" style="text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Celldex Therapeutics, Inc.
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 4%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 4%">
          &#160;
        </td>
        <td style="width: 36%">

        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 36%">

        </td>
        <td style="width: 11%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 5%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated:
          </p>
        </td>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 25%" valign="top">
          March 3, 2011
        </td>
        <td style="width: 15%">

        </td>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 4%" valign="top">
          By:
        </td>
        <td style="border-bottom: solid black 1.0pt; width: 4%">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 0.0px; width: 36%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Avery W. Catlin
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 36%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Avery W. Catlin
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 36%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Senior Vice President and
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 25%">

        </td>
        <td style="width: 15%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="width: 4%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 36%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
        <td style="width: 11%">

        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      Exhibit Index<br>
    </p>
    <p style="text-align: center">

    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 10pt; margin-left:auto;margin-right:auto; width: 100%">
      <tr>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px; width: 5%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            99.1
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 5%" valign="top">
          &#160;
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 90%" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press Release of Celldex Therapeutics, Inc., dated March 3, 2011.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: left">

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a6633053-ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Celldex
      Reports Fourth Quarter and Fiscal 2010 Financial Results</b></font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>-
      Management to Host Conference Call to Discuss Results and Provide 2011
      Outlook Today, Thursday, March 3, at 8:30 a.m. Eastern Time -</b></font>
    </p>
    <p>
      NEEDHAM, Mass.--(BUSINESS WIRE)--March 3, 2011--Celldex Therapeutics,
      Inc. (NASDAQ: CLDX) today reported financial results for the fourth
      quarter and the year ended December 31, 2010. Celldex reported net
      income of $22.7 million, or $0.71 basic earnings per share, and $0.70
      fully diluted earnings per share for the fourth quarter of 2010 compared
      to a net loss of $12.9 million, or ($0.41) per basic and diluted share,
      for the fourth quarter of 2009. Net income for the fourth quarter of
      2010 includes one-time items totaling $30.5 million for rindopepimut
      (CDX-110) related revenue recorded as a result of the termination of the
      Pfizer license agreement and a charge to royalty expense related to
      costs originally capitalized in connection with the Pfizer license
      agreement. Celldex regained rights to rindopepimut during the fourth
      quarter of 2010.
    </p>
    <p>
      Excluding these one-time items, on a non-GAAP basis, Celldex would have
      reported a net loss of $7.8 million, or ($0.24) per basic share, for the
      fourth quarter of 2010. A reconciliation of GAAP to non-GAAP earnings
      (loss) per share is attached.
    </p>
    <p>
      For the twelve months ended December 31, 2010, Celldex reported a net
      loss of $2.5 million, or ($0.08) per share, compared to a net loss of
      $36.5 million, or ($1.84) per share, for the twelve months ended
      December 31, 2009. Net loss for 2010 included the one-time items
      described above. Excluding these items, the non-GAAP net loss per share
      for 2010 was $33.0 million, or ($1.04) per share.
    </p>
    <p>
      &#8220;Celldex enters 2011 well positioned with several product candidates in
      later stage clinical development and two additional programs poised to
      enter clinical studies later this year,&#8221; said Anthony S. Marucci,
      President and Chief Executive Officer. &#8220;We are excited to regain rights
      to develop and commercialize rindopepimut. We are in a strong financial
      position, with projected cash flow and financial resources expected to
      sufficiently fund planned program development into 2012, including
      initiation of a Phase 3 pivotal study for rindopepimut. Our therapeutic
      vaccine, antibody drug-conjugate and therapeutic antibody programs will
      drive a number of potential value enhancing key events over the course
      of this year and next and we look forward to updating shareholders on
      our continued progress and overall strategic initiatives.&#8221;
    </p>
    <div style="margin-bottom: 10pt; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Fourth Quarter and Recent Highlights</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Effective November 1, 2010, Celldex regained rights to develop and
        commercialize rindopepimut. Rindopepimut (CDX 110) is widely perceived
        by clinicians as one of the most promising drug candidates for
        patients with glioblastoma multiforme (GBM)&#8212;a population with very
        limited treatment options&#8212;and we are well positioned to advance
        rindopepimut into a pivotal study in the second half of 2011.
      </li>
      <li style="margin-bottom: 10.0px">
        At the Society for Neuro-Oncology (SNO) Annual Meeting in November,
        Celldex presented complete data for the primary endpoint of ACT III, a
        multi-center, single arm, Phase 2 clinical trial of rindopepimut in
        patients with newly diagnosed GBM. The data showed 66% of patients
        were progression-free at 8.5 months from diagnosis, a statistically
        significant increase over a predetermined progression-free rate (PFR)
        estimate. These encouraging data are consistent with previous studies
        (ACTIVATE and ACT II) with rindopepimut in GBM and provided additional
        information to design the future clinical development of rindopepimut.
      </li>
      <li style="margin-bottom: 10.0px">
        During the fourth quarter 2010, Celldex received Qualifying
        Therapeutic Discovery Project (QTDP) grants totaling approximately
        $1.7 million from the U.S. government related to seven of the
        Company&#8217;s projects.
      </li>
      <li style="margin-bottom: 10.0px">
        Celldex and its collaborators presented positive, preliminary data
        from the CDX-1401 Phase 1/2 study at the iSBTc Annual Meeting in
        October. Robust anti-NY-ESO-1 immunity was induced with the majority
        of the patients developing anti-NY-ESO-1 antibody responses and 39% of
        the patients experiencing increases in NY-ESO-1 specific T cell
        responses including both CD4 and CD8 responses. CDX-1401 was well
        tolerated and there were no dose-limiting toxicities.
      </li>
      <li style="margin-bottom: 10.0px">
        To help meet Celldex&#8217;s anticipated liquidity needs to support the
        ongoing clinical development of its later-stage programs, to payoff
        certain debt obligations and to provide funding for future working
        capital and general corporate purposes, Celldex recently entered into
        two financing transactions that the Company believes will extend its
        liquidity and cash resources&#8212;(i) a debt facility with MidCap
        Financial, LLC pursuant to which the Company borrowed an aggregate of
        $10 million to retire the approximately $12.8 million of outstanding
        principal and accrued interest owed to holders of the Company&#8217;s 4%
        convertible subordinated debt which was paid off on February 14, 2011
        and (ii) a controlled equity offering facility with Cantor
        Fitzgerald&#160;&amp; Co. (&#8220;Cantor&#8221;) pursuant to which the Company may issue
        and sell up to 5,000,000 shares of its common stock from time to time
        through Cantor, acting as agent. Sales of our common stock through
        Cantor, if any, will be made on the NASDAQ Global Market by means of
        ordinary brokers&#8217; transactions at market prices, in block transactions
        or as otherwise agreed by Cantor and Celldex. To date, no sales have
        been made under the controlled equity offering facility.
      </li>
    </ul>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Key 2011 Objectives</b>
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Based on ongoing discussions with the FDA, initiate an international,
        double-blinded, placebo-controlled, randomized Phase 3 pivotal study
        of rindopepimut in approximately 300 patients with GBM that express
        EGFRvIII during the second half of 2011.
      </li>
      <li style="margin-bottom: 10.0px">
        Complete enrollment of the 120-patient randomized Phase 2b controlled
        study of CDX-011, the Company&#8217;s antibody drug conjugate for the
        treatment of patients with glycoprotein NMB (GPNMB)-expressing
        advanced, refractory breast cancer including triple negative disease.
      </li>
      <li style="margin-bottom: 10.0px">
        Initiate Phase 1 clinical studies of CDX-301, or Mobista<sup>TM</sup>,
        and CDX-1127.
      </li>
    </ul>
    <p>
      <b>Further Financial Highlights</b>
    </p>
    <p>
      The increase in income of $35.6 million between the fourth quarters of
      2010 and 2009 is primarily due to one-time items of $35.6 million in
      product development and licensing revenues recorded as a result of the
      termination of the Pfizer license agreement and a $5.1 million charge to
      royalty expense related to costs originally capitalized in connection
      with the Pfizer license agreement. The increase was also due to lower
      research and development (R&amp;D) and general and administrative (G&amp;A)
      expenses in 2010 versus 2009. R&amp;D expense in the fourth quarter of 2010
      decreased by $1.4 million compared to R&amp;D expense in 2009 due primarily
      to lower clinical trials and facility-related costs in 2010 and
      severance expenses incurred in 2009 as a result of the CuraGen
      acquisition. G&amp;A expenses in the fourth quarter of 2010 decreased to
      $2.6 million as compared to $6.4 million in 2009. G&amp;A expenses for the
      2009 fourth quarter included approximately $3.8 million, or $0.12 per
      share, of transaction, severance and integration expenses recorded in
      connection with the CuraGen acquisition. The increase in cash, cash
      equivalents and marketable securities of $3.4 million from September 30,
      2010 includes $10 million received to refinance our debt and $1.6
      million received from QTDP grants, partially offset by our fourth
      quarter operations-related cash burn of approximately $8.2 million.
    </p>
    <p>
      The net loss of $2.5 million for 2010 represents an improvement of $34.0
      million, when compared to the net loss of $36.5 million for the same
      period in 2009, and is primarily due to the two one-time items discussed
      in the prior paragraph. R&amp;D expense in 2010 increased by $1.5 million
      compared to R&amp;D expense in 2009 and was primarily a result of combining
      Celldex and former CuraGen operations for the full year in 2010. R&amp;D
      expenses included increased personnel-related expenses, license fees and
      facility-related costs, offset partially by lower laboratory supplies
      and services costs. G&amp;A expenses decreased by $6.7 million to $10.4
      million in 2010 as compared to G&amp;A expense of $17.1 million in 2009,
      primarily due to severance expense of $3.3 million and increased
      professional service-related fees of $2.6 million incurred in 2009 as a
      result of the CuraGen acquisition.
    </p>
    <p>
      As of December 31, 2010, Celldex had approximately 32.1 million shares
      outstanding.
    </p>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <u><i>Important Information Related to Celldex&#8217;s Financial Results</i></u>
    </p>
    <p>
      <b>CuraGen Acquisition Financial Details</b>
    </p>
    <p>
      On October 1, 2009, CuraGen Corporation, formerly a publicly-traded
      company, merged with a wholly-owned subsidiary of Celldex (the &#8220;CuraGen
      Merger&#8221;). In connection with the CuraGen Merger, Celldex issued a total
      of 15,722,713 shares of Celldex common stock, assumed stock options
      exercisable into 931,315 shares of Celldex common stock and assumed the
      obligation for the $12.5 million in CuraGen 4% convertible subordinated
      debt due in February 2011 (which has now been repaid). Accordingly, the
      results of operations of CuraGen were included in the results of
      operations of Celldex beginning October 1, 2009. CuraGen was then merged
      into Celldex on December 31, 2009 and the separate corporate existence
      of CuraGen ceased.
    </p>
    <p>
      <u><i>Webcast and Conference Call</i></u>
    </p>
    <p>
      Celldex will host a conference call and live audio webcast at 8:30 a.m.
      ET on Thursday, March 3, 2011, to discuss Celldex&#8217;s fourth quarter and
      twelve month 2010 financial results and to provide an update on
      anticipated research and development and business objectives for 2011.
      The conference call and presentation will be webcast live over the
      Internet and can be accessed by logging on to the Events Calendar under
      the &quot;News &amp; Events&quot; section of the Celldex Therapeutics website at <u>www.celldextherapeutics.com</u>.
      The call can also be accessed by dialing 888-713-4218 (within the United
      States) or 617-213-4870 (outside the United States). The passcode for
      participants is 68508575.
    </p>
    <p>
      A replay of the call will be available approximately two hours after the
      live call concludes through March 17, 2011. To access the replay, dial
      888-286-8010 (within the United States) or 617-801-6888 (outside the
      United States). The passcode is 18594660. The webcast will also be
      archived on the Company&#8217;s website. Additionally, a copy of this press
      release is available by contacting Investor Relations at 781-433-0771.
    </p>
    <p>
      <b>About Celldex Therapeutics, Inc.</b>
    </p>
    <p>
      Celldex Therapeutics is the first antibody-based combination
      immunotherapy company. Celldex has a pipeline of drug candidates in
      development for the treatment of cancer and other difficult-to-treat
      diseases based on its antibody focused Precision Targeted Immunotherapy
      Platform. The PTI Platform is a complementary portfolio of monoclonal
      antibodies, antibody-targeted vaccines and immunomodulators used in
      optimal combinations to create novel disease-specific drug candidates.
      For more information, please visit <u>http://www.celldextherapeutics.com</u>.
    </p>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Safe Harbor Statement Under the Private Securities Litigation Reform
      Act of 1995:</b> <i>This release contains &#8220;forward-looking statements&#8221;
      made pursuant to the safe harbor provisions of the Private Securities
      Litigation Reform Act of 1995, including those related to the Company&#8217;s
      strategic focus and the future development and commercialization (by
      Celldex and others) of rindopepimut (CDX-110), CDX-1307, CDX-011,
      CDX-1135 (formerly TP10), CDX-1401, Belinostat and other products</i>. <i>Forward-looking
      statements reflect management's current knowledge, assumptions, judgment
      and expectations regarding future performance or events. Although
      management believes that the expectations reflected in such statements
      are reasonable, they give no assurance that such expectations will prove
      to be correct and you should be aware that actual results could differ
      materially from those contained in the forward-looking statements.
      Forward-looking statements are subject to a number of risks and
      uncertainties, including, but not limited to, our ability to
      successfully integrate the businesses, multiple technologies and
      programs of CuraGen and Celldex; our ability to adapt APC Targeting
      Technology<sup>TM</sup> to develop new, safe and effective vaccines
      against oncology and infectious disease indications; our ability to
      successfully complete product research and further development of our
      programs, including rindopepimut, which, effective November 1, 2010, is
      at our cost; the uncertainties inherent in clinical testing; our limited
      experience in bringing programs through Phase 3 clinical trials; our
      ability to manage research and development efforts for multiple products
      at varying stages of development; our strategy and business plans
      concerning the continued development and commercialization of
      rindopepimut; our ability to successfully complete the transition of
      rindopepimut from Pfizer to Celldex; the timing, cost and uncertainty of
      obtaining regulatory approvals; the failure of the market for the
      Company's programs to continue to develop; our limited cash reserves and
      our ability to obtain additional capital on acceptable terms, or at all;
      our ability to protect the Company&#8217;s intellectual property; the loss of
      any executive officers or key personnel or consultants; competition;
      changes in the regulatory landscape or the imposition of regulations
      that affect the Company&#8217;s products; and other factors listed under &#8220;Risk
      Factors&#8221; in our annual report on Form 10-K.</i>
    </p>
    <p>
      <i>All forward-looking statements are expressly qualified in their
      entirety by this cautionary notice. You are cautioned not to place undue
      reliance on any forward-looking statements, which speak only as of the
      date of this release. We have no obligation, and expressly disclaim any
      obligation, to update, revise or correct any of the forward-looking
      statements, whether as a result of new information, future events or
      otherwise.</i>
    </p>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 8pt; width: 100%">
      <tr>
        <td colspan="17">
          &#160;
        </td>
      </tr>
      <tr>
        <td colspan="17" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>CELLDEX THERAPEUTICS, INC.</b>
        </td>
      </tr>
      <tr>
        <td colspan="17" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>(In thousands, except per share amounts)</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          <b>CONSOLIDATED STATEMENTS</b>
        </td>
        <td>

        </td>
        <td colspan="7" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>Quarter Ended</b>
        </td>
        <td>

        </td>
        <td colspan="7" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>Year Ended</b>
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          <b>OF OPERATIONS DATA</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td colspan="7" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px" valign="top">
          <b>December 31,</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td colspan="7" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px" valign="top">
          <b>December 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2010</b>
        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2009</b>
        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2010</b>
        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2009</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="7" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>(Unaudited)</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          <b>REVENUE</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Product Development and
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 25.0px" valign="top">
          Licensing Agreements
        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          36,070
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          1,324
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          40,187
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          5,662
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Contracts and Grants
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          863
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          220
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          1,802
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Product Royalties
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          1,651
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          2,546
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          6,386
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          7,716
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Total Revenue
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          37,721
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          4,733
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          46,793
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          15,180
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          <b>OPERATING EXPENSE</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Research and Development
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          6,741
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          8,111
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          27,650
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          26,169
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Royalty
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          6,800
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          2,727
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          12,077
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          8,397
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          General and Administrative
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          2,581
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          6,419
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          10,428
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          17,119
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Gain on Sale of Assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (50
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (604
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Amortization of Acquired Intangible Assets
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          483
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          662
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          3,143
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          949
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Total Operating Expense
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          16,605
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          17,919
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          53,248
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          52,030
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Operating Income (Loss)
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          21,116
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (13,186
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (6,455
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (36,850
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Investment and Other Income, Net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          1,880
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          54
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          5,259
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          248
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Interest Expense
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (335
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (340
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1,337
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (452
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Net Income (Loss) Before Income Tax
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          22,661
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (13,472
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (2,533
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (37,054
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Income Tax Benefit
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          529
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          529
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Net Income (Loss)
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          22,661
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (12,943
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (2,533
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (36,525
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Net Income (Loss) per Common Share - Basic
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          0.71
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.41
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.08
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1.84
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          Net Income (Loss) per Common Share - Diluted
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          0.70
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.41
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.08
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1.84
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px" valign="top">
          Weighted Average Common Shares Outstanding:
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 25.0px" valign="top">
          Basic
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          32,037
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          31,629
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          31,868
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          19,823
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 25.0px" valign="top">
          Diluted
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          32,191
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          31,629
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          31,868
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          19,823
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 8pt; width: 100%">
      <tr>
        <td colspan="11">
          &#160;
        </td>
      </tr>
      <tr>
        <td colspan="11" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>CELLDEX THERAPEUTICS, INC.</b>
        </td>
      </tr>
      <tr>
        <td colspan="11" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>(In thousands)</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          <b>CONDENSED CONSOLIDATED</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-left: 5.0px" valign="top">
          <b>BALANCE SHEETS</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td colspan="2" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px" valign="top">
          <b>December 31,</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td colspan="2" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px" valign="top">
          <b>December 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td colspan="2" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2010</b>
        </td>
        <td>

        </td>
        <td colspan="2" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2009</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          <b>ASSETS</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Cash, Cash Equivalents and Marketable Securities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          61,098
        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          82,453
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Other Current Assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          1,849
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          1,523
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Property and Equipment, net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          10,832
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          11,489
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px" valign="top">
          Intangible and Other Assets, net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          36,164
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          44,899
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 4.0px; padding-left: 25.0px" valign="top">
          Total Assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          109,943
        </td>
        <td>

        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          140,364
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Current Liabilities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          20,208
        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          14,407
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Long-Term Liabilities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          14,480
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          52,190
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px" valign="top">
          Stockholders' Equity
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          75,255
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          73,767
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 4.0px; padding-left: 25.0px" valign="top">
          Total Liabilities and Stockholders' Equity
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          109,943
        </td>
        <td>

        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: double black 2.25pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          140,364
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; margin-right: 0pt; text-indent: 0pt; margin-left: 0pt; width: 100%">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 8pt; width: 100%">
      <tr>
        <td colspan="17">
          &#160;
        </td>
      </tr>
      <tr>
        <td colspan="17" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>CELLDEX THERAPEUTICS, INC.</b>
        </td>
      </tr>
      <tr>
        <td colspan="17" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>CONSOLIDATED STATEMENTS OF OPERATIONS DATA</b>
        </td>
      </tr>
      <tr>
        <td colspan="17" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>(In thousands, except per share amounts)</b>
        </td>
      </tr>
      <tr>
        <td colspan="17" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>(Unaudited)</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="7" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>Quarter Ended</b>
        </td>
        <td>

        </td>
        <td colspan="7" style="text-align: center; padding-left: 0.0px" valign="top">
          <b>Year Ended</b>
        </td>
      </tr>
      <tr>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td colspan="7" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px" valign="top">
          <b>December 31,</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td colspan="7" style="border-bottom: solid black 1.0pt; text-align: center; padding-left: 0.0px" valign="top">
          <b>December 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2010</b>
        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2009</b>
        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2010</b>
        </td>
        <td>

        </td>
        <td colspan="3" style="text-align: center; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          <b>2009</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Reconcilitation of basic net income (loss) per
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 25.0px" valign="top">
          share, in accordance with generally
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 25.0px" valign="top">
          accepted accounting principles, with
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 25.0px" valign="top">
          adjusted results:
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px" valign="top">
          Net income (loss) per basic share
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          0.71
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.41
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.08
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1.84
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          Adjustment for the termination of the Pfizer
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 25.0px" valign="top">
          license agreement
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (35,594
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (35,594
        </td>
        <td style="text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px" valign="top">
          Net loss per basic share effect
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1.11
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1.12
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 5.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Adjustment for costs capitalized in connection
          </p>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 25.0px" valign="top">
          the Pfizer license agreement
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          5,089
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          5,089
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px" valign="top">
          Net income per basic share effect
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          0.16
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          0.16
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          -
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 5.0px" valign="top">
          Adjusted net loss per basic share
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.24
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (0.41
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1.04
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          $
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: right; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          (1.84
        </td>
        <td style="border-bottom: solid black 1.0pt; text-align: left; padding-right: 0.0px; white-space: nowrap; padding-left: 0.0px" valign="bottom">
          )
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; font-size: 8pt; width: 100%">
      <tr>
        <td style="text-align: left; padding-left: 0.0px" valign="top">
          The adjusted net loss per basic share presented above is not in
          accordance with generally accepted
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px" valign="top">
          accounting principles (GAAP). The above reconciliation identifies
          one-time items that resulted from Pfizer's
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            termination of its rindopepimut license agreement with Celldex
            which management believes are not directly related to
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px" valign="top">
          ongoing operations. Management has excluded these items from its
          non-GAAP adjusted amounts, thereby providing
        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px" valign="top">
          investors with information that may help them to compare ongoing
          operating performance.
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      CONTACT:<br>Celldex Therapeutics, Inc.<br>Anthony S. Marucci,
      781-433-0771<br>President and CEO<br>or<br>Celldex Therapeutics, Inc.<br>Avery
      W. Catlin, 781-433-0771<br>Chief Financial Officer<br><u>IR@celldextherapeutics.com</u><br>or<br><u>For
      Media:</u><br>BMC Communications Group<br>Matthew Driscoll, 212-477-9007
      x20<br><u>mdriscoll@bmccommunications.com</u>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
